Amedeo Smart

Free Medical Literature Service



Liver Diseases

  Free Subscription

Articles published in
    August 2021
  1. HARDING JJ, Yang TS, Chen YY, Feng YH, et al
    Assessment of pegylated arginine deiminase and modified FOLFOX6 in patients with advanced hepatocellular carcinoma: Results of an international, single-arm, phase 2 study.
    Cancer. 2021 Aug 20. doi: 10.1002/cncr.33870.
    >> Share

    July 2021
  2. MERRIAM P, Nathenson MJ
    Liver transplantation for hepatic epithelioid hemangioendothelioma.
    Cancer. 2021 Jul 13. doi: 10.1002/cncr.33751.
    >> Share

  3. DING X, Sun W, Li W, Shen Y, et al
    Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study.
    Cancer. 2021 Jul 8. doi: 10.1002/cncr.33677.
    >> Share

    February 2021
  4. SHALTIEL T, Zheng S, Siderides C, Gleeson EM, et al
    Hepatitis C-positive Black patients develop hepatocellular carcinoma at earlier stages of liver disease and present with a more aggressive phenotype.
    Cancer. 2021 Feb 25. doi: 10.1002/cncr.33377.
    >> Share

    Racial disparities in hepatocellular carcinoma.
    Cancer. 2021 Feb 25. doi: 10.1002/cncr.33376.
    >> Share

    November 2020
  6. RYOO BY, Merle P, Kulkarni AS, Cheng AL, et al
    Health-related quality-of-life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE-240.
    Cancer. 2020 Nov 24. doi: 10.1002/cncr.33317.
    >> Share

  7. DI GIUSEPPE G, Youlden DR, Aitken JF, Pole JD, et al
    Pediatric hepatic cancer incidence and survival: 30-year trends in Ontario, Canada; the United States; and Australia.
    Cancer. 2020 Nov 16. doi: 10.1002/cncr.33319.
    >> Share

    October 2020
  8. WONG RJ, Kim D, Ahmed A, Singal AK, et al
    Patients with hepatocellular carcinoma from more rural and lower income households have more advanced tumor stage at diagnosis and significantly higher mortality.
    Cancer. 2020 Oct 26. doi: 10.1002/cncr.33211.
    >> Share

    April 2020
  9. FIALA EM, Ortiz MV, Kennedy JA, Glodzik D, et al
    11p15.5 epimutations in children with Wilms tumor and hepatoblastoma detected in peripheral blood.
    Cancer. 2020 Apr 22. doi: 10.1002/cncr.32907.
    >> Share

    March 2020
  10. KOBAYASHI H, Iwata S, Wakamatsu T, Hayakawa K, et al
    Efficacy and safety of trabectedin for patients with unresectable and relapsed soft-tissue sarcoma in Japan: A Japanese Musculoskeletal Oncology Group study.
    Cancer. 2020;126:1253-1263.
    >> Share

  11. FLORIO AA, Ferlay J, Znaor A, Ruggieri D, et al
    Global incidence of and trends in intrahepatic and extrahepatic cholangiocarcinoma from 1993 to 2012.
    Cancer. 2020 Mar 4. doi: 10.1002/cncr.32803.
    >> Share

    January 2020
  12. UPPAL A, Smieliauskas F, Sharma MR, Maron SB, et al
    Facilities that service economically advantaged neighborhoods perform surgical metastasectomy more often for patients with colorectal liver metastases.
    Cancer. 2020;126:281-292.
    >> Share

    November 2019
  13. JANG WI, Bae SH, Kim MS, Han CJ, et al
    A phase 2 multicenter study of stereotactic body radiotherapy for hepatocellular carcinoma: Safety and efficacy.
    Cancer. 2019 Nov 20. doi: 10.1002/cncr.32502.
    >> Share

    July 2019
  14. WU L, Tsilimigras DI, Farooq A, Hyer JM, et al
    Management and outcomes among patients with sarcomatoid hepatocellular carcinoma: A population-based analysis.
    Cancer. 2019 Jul 12. doi: 10.1002/cncr.32396.
    >> Share

  15. HESTER CA, Karbhari N, Rich NE, Augustine M, et al
    Effect of fragmentation of cancer care on treatment use and survival in hepatocellular carcinoma.
    Cancer. 2019 Jul 12. doi: 10.1002/cncr.32336.
    >> Share

  16. EL DIKA I, Khalil DN, Abou-Alfa GK
    Immune checkpoint inhibitors for hepatocellular carcinoma.
    Cancer. 2019 Jul 10. doi: 10.1002/cncr.32076.
    >> Share

    June 2019
  17. FEUN LG, Li YY, Wu C, Wangpaichitr M, et al
    Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma.
    Cancer. 2019 Jun 28. doi: 10.1002/cncr.32339.
    >> Share

  18. MA J, Siegel RL, Islami F, Jemal A, et al
    Temporal trends in liver cancer mortality by educational attainment in the United States, 2000-2015.
    Cancer. 2019;125:2089-2098.
    >> Share

  19. KAMBHAMPATI S, Bauer KE, Bracci PM, Keenan BP, et al
    Nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh class B cirrhosis: Safety and clinical outcomes in a retrospective case series.
    Cancer. 2019 Jun 2. doi: 10.1002/cncr.32206.
    >> Share

    May 2019
  20. PHILIPS CA, Rajesh S, John SK, Valiathan GC, et al
    Traditional herbal medicine for liver cancer: "Let's pretend I like cooking and you pretend it tastes nice".
    Cancer. 2019;125:1568-1569.
    >> Share

  21. LING C
    Reply to Traditional herbal medicine for liver cancer: "Let's pretend I like cooking and you pretend it tastes nice".
    Cancer. 2019;125:1569-1570.
    >> Share

    April 2019
  22. SHIELS MS, Engels EA, Yanik EL, McGlynn KA, et al
    Incidence of hepatocellular carcinoma among older Americans attributable to hepatitis C and hepatitis B: 2001 through 2013.
    Cancer. 2019 Apr 12. doi: 10.1002/cncr.32129.
    >> Share

    March 2019
  23. KANTARJIAN HM, DeAngelo DJ, Stelljes M, Liedtke M, et al
    Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study.
    Cancer. 2019 Mar 28. doi: 10.1002/cncr.32116.
    >> Share

  24. ENDESHAW M, Hallowell BD, Razzaghi H, Senkomago V, et al
    Trends in liver cancer mortality in the United States: Dual burden among foreign- and US-born persons.
    Cancer. 2019;125:726-734.
    >> Share

    January 2019
  25. VAN DYKE AL, Shiels MS, Jones GS, Pfeiffer RM, et al
    Biliary tract cancer incidence and trends in the United States by demographic group, 1999-2013.
    Cancer. 2019 Jan 15. doi: 10.1002/cncr.31942.
    >> Share

    December 2018
  26. NAZHA B, Owonikoko TK
    The clinical conundrum of managing relapsed small cell lung cancer.
    Cancer. 2018 Dec 18. doi: 10.1002/cncr.31849.
    >> Share

    November 2018
  27. YI SW, Choi JS
    Reply to Risk factors for hepatocellular carcinoma.
    Cancer. 2018 Nov 30. doi: 10.1002/cncr.31801.
    >> Share

  28. LAI SW
    Risk factors for hepatocellular carcinoma.
    Cancer. 2018 Nov 30. doi: 10.1002/cncr.31802.
    >> Share

    August 2018
  29. YANG B, Liu JB, So SK, Han SS, et al
    Disparities in Hepatocellular Carcinoma Incidence by Race/Ethnicity and Geographic Area in California: Implications for Prevention.
    Cancer. 2018 Aug 16. doi: 10.1002/cncr.31598.
    >> Share

    April 2018
  30. YI SW, Choi JS, Yi JJ, Lee YH, et al
    Risk factors for hepatocellular carcinoma by age, sex, and liver disorder status: A prospective cohort study in Korea.
    Cancer. 2018 Apr 18. doi: 10.1002/cncr.31406.
    >> Share

  31. ERSTAD DJ, Fuchs BC, Tanabe KK
    Molecular signatures in hepatocellular carcinoma: A step toward rationally designed cancer therapy.
    Cancer. 2018 Apr 17. doi: 10.1002/cncr.31257.
    >> Share

  32. CHINO F, Stephens SJ, Choi SS, Marin D, et al
    The role of external beam radiotherapy in the treatment of hepatocellular cancer.
    Cancer. 2018 Apr 12. doi: 10.1002/cncr.31334.
    >> Share

  33. KIM NG, Nguyen PP, Dang H, Kumari R, et al
    Temporal trends in disease presentation and survival of patients with hepatocellular carcinoma: A real-world experience from 1998 to 2015.
    Cancer. 2018 Apr 6. doi: 10.1002/cncr.31373.
    >> Share

    March 2018
  34. COSTENTIN CE, Mourad A, Lahmek P, Causse X, et al
    Hepatocellular carcinoma is diagnosed at a later stage in alcoholic patients: Results of a prospective, nationwide study.
    Cancer. 2018 Mar 28. doi: 10.1002/cncr.31215.
    >> Share

  35. GILL H, Yim R, Lee HKK, Mak V, et al
    Long-term outcome of relapsed acute promyelocytic leukemia treated with oral arsenic trioxide-based reinduction and maintenance regimens: A 15-year prospective study.
    Cancer. 2018 Mar 26. doi: 10.1002/cncr.31327.
    >> Share

  36. TSAI KK, Bollin KB, Patel SP
    Obstacles to improving outcomes in the treatment of uveal melanoma.
    Cancer. 2018 Mar 26. doi: 10.1002/cncr.31284.
    >> Share

  37. ZHAI XF, Liu XL, Shen F, Fan J, et al
    Traditional herbal medicine prevents postoperative recurrence of small hepatocellular carcinoma: A randomized controlled study.
    Cancer. 2018 Mar 2. doi: 10.1002/cncr.30915.
    >> Share

    February 2018
  38. KIM HS, Shaib WL, Zhang C, Nagaraju GP, et al
    Phase 1b study of pasireotide, everolimus, and selective internal radioembolization therapy for unresectable neuroendocrine tumors with hepatic metastases.
    Cancer. 2018 Feb 16. doi: 10.1002/cncr.31192.
    >> Share

    January 2018
  39. JABBOUR EJ, DeAngelo DJ, Stelljes M, Stock W, et al
    Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE.
    Cancer. 2018 Jan 30. doi: 10.1002/cncr.31249.
    >> Share

  40. NEUWIRTH MG, Bierema C, Sinnamon AJ, Fraker DL, et al
    Trends in major upper abdominal surgery for cancer in octogenarians: Has there been a change in patient selection?
    Cancer. 2018;124:125-135.
    >> Share

    December 2017
  41. MOMIN BR, Pinheiro PS, Carreira H, Li C, et al
    Liver cancer survival in the United States by race and stage (2001-2009): Findings from the CONCORD-2 study.
    Cancer. 2017;123 Suppl 24:5059-5078.
    >> Share

    October 2017
  42. MOKDAD AA, Murphy CC, Pruitt SL, Mansour JC, et al
    Effect of hospital safety net designation on treatment use and survival in hepatocellular carcinoma.
    Cancer. 2017 Oct 26. doi: 10.1002/cncr.31066.
    >> Share

    August 2017
  43. TRAN CAO HS, Zhang Q, Sada YH, Chai C, et al
    The role of surgery and adjuvant therapy in lymph node-positive cancers of the gallbladder and intrahepatic bile ducts.
    Cancer. 2017 Aug 25. doi: 10.1002/cncr.30968.
    >> Share

  44. MEDHANIE GA, Fedewa SA, Adissu H, DeSantis CE, et al
    Cancer incidence profile in sub-Saharan African-born blacks in the United States: Similarities and differences with US-born non-Hispanic blacks.
    Cancer. 2017;123:3116-3124.
    >> Share

  45. HUNG YP, Lovitch SB, Qian X
    Histiocytic sarcoma: New insights into FNA cytomorphology and molecular characteristics.
    Cancer. 2017;125:604-614.
    >> Share

    July 2017
  46. LEWIS DR, Chen HS, Cockburn MG, Wu XC, et al
    Early estimates of SEER cancer incidence, 2014.
    Cancer. 2017;123:2524-2534.
    >> Share

    June 2017
  47. KASUYA G, Kato H, Yasuda S, Tsuji H, et al
    Progressive hypofractionated carbon-ion radiotherapy for hepatocellular carcinoma: Combined analyses of 2 prospective trials.
    Cancer. 2017 Jun 29. doi: 10.1002/cncr.30816.
    >> Share

  48. LIN YY, Yu MW, Lin SM, Lee SD, et al
    Genome-wide association analysis identifies a GLUL haplotype for familial hepatitis B virus-related hepatocellular carcinoma.
    Cancer. 2017 Jun 29. doi: 10.1002/cncr.30851.
    >> Share

  49. PARIKH ND, Singal AG, Hutton DW
    Cost effectiveness of regorafenib as second-line therapy for patients with advanced hepatocellular carcinoma.
    Cancer. 2017 Jun 29. doi: 10.1002/cncr.30863.
    >> Share

  50. CHAN SL, Yeo W, Mo F, Chan AWH, et al
    A phase 2 study of the efficacy and biomarker on the combination of transarterial chemoembolization and axitinib in the treatment of inoperable hepatocellular carcinoma.
    Cancer. 2017 Jun 22. doi: 10.1002/cncr.30825.
    >> Share

  51. KIM Y, Lee SJ, Lee JY, Lee SH, et al
    Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14-01).
    Cancer. 2017;123:1958-1964.
    >> Share

    May 2017
  52. TARHINI AA, Rafique I, Floros T, Tran P, et al
    Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer.
    Cancer. 2017 May 4. doi: 10.1002/cncr.30717.
    >> Share

    April 2017
  53. ZHOU H, Guo M, Gong Y
    Challenge of FNA diagnosis of angiomyolipoma: A study of 33 cases.
    Cancer. 2017;125:257-266.
    >> Share

    February 2017
  54. HUANG J, Fogg M, Wirth LJ, Daley H, et al
    Epstein-Barr virus-specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma.
    Cancer. 2017 Feb 21. doi: 10.1002/cncr.30541.
    >> Share

  55. FRANKEL TL, Vakiani E, Nathan H, DeMatteo RP, et al
    Mutation location on the RAS oncogene affects pathologic features and survival after resection of colorectal liver metastases.
    Cancer. 2017;123:568-575.
    >> Share

  56. SAHLMANN CO, Homayounfar K, Niessner M, Dyczkowski J, et al
    Repeated adjuvant anti-CEA radioimmunotherapy after resection of colorectal liver metastases: Safety, feasibility, and long-term efficacy results of a prospective phase 2 study.
    Cancer. 2017;123:638-649.
    >> Share

  57. REDDY SK, Boland PM, Nurkin SJ
    Primary tumor resection does not improve survival among patients with unresectable colorectal cancer metastases-But who determines resectability?
    Cancer. 2017 Feb 8. doi: 10.1002/cncr.30595.
    >> Share

    January 2017
  58. PRINTZ C
    Cancer mortality rates vary among specific Asian American ethnic groups.
    Cancer. 2017;123:11.
    >> Share

    September 2016
  59. LORIOT Y, Fizazi K, de Bono JS, Forer D, et al
    Enzalutamide in castration-resistant prostate cancer patients with visceral disease in the liver and/or lung: Outcomes from the randomized controlled phase 3 AFFIRM trial.
    Cancer. 2016 Sep 20. doi: 10.1002/cncr.30336.
    >> Share

    August 2016
  60. SHOUSHTARI AN, Munhoz RR, Kuk D, Ott PA, et al
    The efficacy of anti-PD-1 agents in acral and mucosal melanoma.
    Cancer. 2016 Aug 17. doi: 10.1002/cncr.30259.
    >> Share

    July 2016
  61. CRANE CH, Koay EJ
    Solutions that enable ablative radiotherapy for large liver tumors: Fractionated dose painting, simultaneous integrated protection, motion management, and computed tomography image guidance.
    Cancer. 2016;122:1974-86.
    >> Share

    June 2016
  62. DROOGER JC, van Tinteren H, de Groot SM, Ten Tije AJ, et al
    A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy-free approach in HER2-positive metastatic breast cancer: The HAT study (BOOG 2008-2003), a Dutch Breast Cancer Research Group trial.
    Cancer. 2016 Jun 17. doi: 10.1002/cncr.30141.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016